Briefing Information for the October 25, 2013 Meeting of the Antiviral Drugs Advisory Committee - Sofosbuvir

Persons with disabilities having problems accessing the PDF file(s) below may call (301) 796-3634 for assistance

FDA

Disclaimer: Portions of this document have been determined to be exempt from disclosure under the Freedom of Information Act (the FOIA) (5 U.S.C. § 552).

• FDA Briefing Information for the October 25, 2013 Meeting of the Antiviral Drugs Advisory Committee (PDF - 357KB)¹

Gilead Sciences, Inc.

Disclaimer: The statements contained in this document(s) are those of the product's sponsor, not FDA, and FDA does not necessarily agree with the sponsor's statements. FDA has not made a final determination about the safety or effectiveness of the product described in this document.

• Gilead Briefing Information for the October 25, 2013 Meeting of the Antiviral Drugs Advisory Committee (PDF - 2.5MB)²

Source – FDA